北京大学学报（医学版） ›› 2020, Vol. 52 ›› Issue (3): 597-602. doi: 10.19723/j.issn.1671-167X.2020.03.031
中性粒细胞与淋巴细胞比例对评估接受过继性细胞免疫治疗的晚期胰腺癌患者预后的临床意义
姜妮,乔国梁,王小利,周心娜,周蕾,宋雨光,赵艳杰,任军(
)
- 首都医科大学附属北京世纪坛医院肿瘤内科,肿瘤治疗性疫苗北京市重点实验室,北京 100038
中图分类号:
- R730.51
| [1] |
Del Chiaro M, Segersvard R, Lohr M, et al. Early detection and prevention of pancreatic cancer: is it really possible today?[J]. World J Gastroenterol, 2014,20(34):12118-12131.
doi: 10.3748/wjg.v20.i34.12118 pmid: 25232247 |
| [2] | Yabar CS, Winter JM. Pancreatic cancer: A review[J]. Gas-troenterol Clin North Am, 2016,45(3):429-445. |
| [3] | Zhang Y, Zhang X, Zhang A, et al. Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis[J]. Onco Targets Ther, 2017,10:4173-4192. |
| [4] | Lin M, Liang S, Jiang F, et al. 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage Ⅳ breast cancer[J]. Immunol Lett, 2017,183(3):37-43. |
| [5] |
Koizumi W, Kurihara M, Nakano S, et al. Phase Ⅱ study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group[J]. Oncology, 2000,58(3):191-197.
pmid: 10765119 |
| [6] | Hagihara K, Ikeda M, Maeda S, et al. Effectiveness of irinotecan, S-1, and bevacizumab for rectal cancer with lung and skin metastases after adjuvant chemotherapy[J]. Gan To Kagaku Ryoho, 2016,43(12):2313-2315. |
| [7] |
Ueno H, Ioka T, Ikeda M, et al. Randomized phase Ⅲ study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study[J]. J Clin Oncol, 2013,31(13):1640-1648.
pmid: 23547081 |
| [8] |
Morizane C, Okusaka T, Furuse J, et al. A phase Ⅱ study of S-1 in gemcitabine-refractory metastatic pancreatic cancer[J]. Cancer Chemother Pharmacol, 2009,63(2):313-319.
doi: 10.1007/s00280-008-0741-7 |
| [9] | Jiang N, Qiao G, Wang X-L, et al. Dendritic cell/cytokine induced killer cell immunotherapy combined with S-1 in patients with advanced pancreatic cancer: A prospective study[J]. Clin Cancer Res, 2017,23(17):5066-5073. |
| [10] |
Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy[J]. Curr Opin Oncol, 2013,25(1):50-51.
pmid: 23150341 |
| [11] | Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism[J]. Cancer Res, 2000,60(1):184-190. |
| [12] |
He W, Yin C, Guo G, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer[J]. Med Oncol, 2013,30(1):439.
pmid: 23307251 |
| [13] |
Luo G, Liu C, Cheng H, et al. Neutrophil-lymphocyte ratio predicts survival in pancreatic neuroendocrine tumors[J]. Oncol Lett, 2017,13(4):2454-2458.
pmid: 28454419 |
| [14] |
Chen Y, Yan H, Wang Y, et al. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma[J]. Sci Rep, 2017,7(1):753.
pmid: 28392554 |
| [15] |
Formica V, Morelli C, Ferroni P, et al. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin[J]. Cancer Biomark, 2016,17(3):335-345.
pmid: 27434293 |
| [16] |
Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences[J]. Clin Transl Oncol, 2013,15(10):780-788.
pmid: 23359185 |
| [17] | 王艺, 王理伟. 胰腺癌患者免疫状态及免疫治疗进展[J]. 肿瘤, 2018,38(6):610-616. |
| [18] |
Meng Y, Yu Z, Wu Y, et al. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application[J]. Hum Vaccin Immunother, 2017,13(6):1-9.
pmid: 28301266 |
| [19] |
Chen J, Chen Y, Feng F, et al. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer[J]. J Thorac Dis, 2018,10(12):6711-6721.
pmid: 30746216 |
| [20] |
Wang Q, Liu Y, Chen Y, et al. CD300LG improves the cytotoxic activity of CIK[J]. Cent Eur J Immunol, 2017,42(2):117-122.
pmid: 28860929 |
| [21] |
Xue P, Kanai M, Mori Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients[J]. Cancer Med, 2014,3(2):406-415.
pmid: 24519894 |
| [22] |
Li Y, Wang C, Xu M, et al. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer[J]. J Cancer Res Clin Oncol, 2017,143(5):861-871.
doi: 10.1007/s00432-016-2330-1 pmid: 28108815 |
| [23] |
Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor[J]. Angiogenesis, 2003,6(4):283-287.
doi: 10.1023/B:AGEN.0000029415.62384.ba pmid: 15166496 |
| [24] |
Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape[J]. Cytokine Growth Factor Rev, 2007,18(1-2):171-182.
doi: 10.1016/j.cytogfr.2007.01.015 pmid: 17329145 |
| [25] |
Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the evelopment and progression of hepatocarcinogenesis[J]. Clin Cancer Res, 2007,13(3):902-911.
doi: 10.1158/1078-0432.CCR-06-2363 pmid: 17289884 |
| [1] | 田佳宜,张霞,程功,刘庆红,王世阳,何菁. 系统性红斑狼疮患者血清白细胞介素-2受体α水平及其临床意义[J]. 北京大学学报（医学版）, 2021, 53(6): 1083-1087. |
| [2] | 王飞,朱翔,贺蓓,朱红,沈宁. 自发缓解的滤泡性细支气管炎伴非特异性间质性肺炎1例报道并文献复习[J]. 北京大学学报（医学版）, 2021, 53(6): 1196-1200. |
| [3] | 高伟波,石茂静,张海燕,吴春波,朱继红. 显著高铁蛋白血症与噬血细胞性淋巴组织细胞增多症的相互关系[J]. 北京大学学报（医学版）, 2021, 53(5): 921-927. |
| [4] | 张梅香,史文芝,刘建新,王春键,李燕,王蔚,江滨. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报（医学版）, 2021, 53(5): 915-920. |
| [5] | 蒋艳芳,王健,王永健,刘佳,裴殷,刘晓鹏,敖英芳,马勇. 前交叉韧带翻修重建术后中长期临床疗效及影响因素[J]. 北京大学学报（医学版）, 2021, 53(5): 857-863. |
| [6] | 肖若陶,刘承,徐楚潇,何为,马潞林. 术前血小板参数与局部进展期肾细胞癌预后[J]. 北京大学学报（医学版）, 2021, 53(4): 647-652. |
| [7] | 马向波,张学武,贾汝琳,高颖,刘洪江,刘玉芳,李英妮. 外周血淋巴细胞亚群检测在系统性硬化症治疗中的应用[J]. 北京大学学报（医学版）, 2021, 53(4): 721-727. |
| [8] | 于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报（医学版）, 2021, 53(4): 640-646. |
| [9] | 赵勋,颜野,黄晓娟,董靖晗,刘茁,张洪宪,刘承,马潞林. 癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响[J]. 北京大学学报（医学版）, 2021, 53(4): 665-670. |
| [10] | 陈怀安,刘硕,李秀君,王哲,张潮,李凤岐,苗文隆. 炎症生物标志物对输尿管尿路上皮癌患者预后预测的临床价值[J]. 北京大学学报（医学版）, 2021, 53(2): 302-307. |
| [11] | 高鹏,雒艳萍,李俊峰. B/C基因型的乙型肝炎病毒对不同免疫阶段慢性乙型肝炎患者T淋巴细胞及其亚群的影响[J]. 北京大学学报（医学版）, 2020, 52(6): 1153-1156. |
| [12] | 刘世博,高辉,冯元春,李静,张彤,万利,刘燕鹰,李胜光,罗成华,张学武. 腹膜后纤维化致肾盂积水的临床分析:附17例报道[J]. 北京大学学报（医学版）, 2020, 52(6): 1069-1074. |
| [13] | 包芳,史尉利,胡静,张娣,高东晗,夏云霞,景红梅,克晓燕,葛庆岗,沈宁. 新型冠状病毒肺炎淋巴细胞亚群与严重程度的相关分析[J]. 北京大学学报（医学版）, 2020, 52(6): 1075-1081. |
| [14] | 陈伟钱,戴小娜,余叶,王沁,梁钧昱,柯旖旎,易彩虹,林进. 原发性干燥综合征合并自身免疫性肝病的临床特点及预后分析[J]. 北京大学学报（医学版）, 2020, 52(5): 886-891. |
| [15] | 马茹,李鑫宝,闫风彩,林育林,李雁. 肿瘤间质比评估阑尾来源腹膜假黏液瘤的临床价值[J]. 北京大学学报（医学版）, 2020, 52(2): 240-246. |
|
